129 results on '"Arhin, Francis"'
Search Results
2. In vitro activity of aztreonam-avibactam and comparators against Metallo-β-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016–2020
3. Supply chain collaboration of Ghana's gold mining industry
4. Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019
5. In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019
6. Analyzing the impact of environmental collaboration among supply chain stakeholders on a firm’s sustainable performance
7. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci
8. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015
9. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus
10. In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020.
11. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020.
12. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus
13. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011–2014
14. Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci
15. Antimicrobial Activity of Ceftazidime–Avibactam and Comparators Against Fluoroquinolone-Resistant Klebsiella pneumoniae Collected Globally from Antimicrobial Testing Leadership and Surveillance: 2018–2019.
16. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017
17. Time–kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes
18. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital
19. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis
20. Inhibition of transcription in Staphylococcus aureus by a primary sigma factor-binding polypeptide from phage G1
21. A new class of small molecule RNA polymerase inhibitors with activity against Rifampicin-resistant Staphylococcus aureus
22. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin
23. Time–kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium
24. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
25. Outer Membrane Proteins and Serosubtyping with Outer Membrane Vesicles from Clinical Isolates of Neisseria meningitidis
26. 11: IN VITRO ACTIVITY OF AZTREONAM-AVIBACTAM AGAINST ENTEROBACTERALES ISOLATES THAT CARRY METALLO-β-LACTAMASES COLLECTED IN THE ASIA/PACIFIC REGIONAS A PART OF THE ATLAS GLOBAL SURVEILLANCE PROGRAM FROM 2015–2020
27. 13: IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND AZTREONAM-AVIBACTAM AGAINST CARBAPENEM-NONSUSCEPTIBLE ENTEROBACTERALES ISOLATES COLLECTED IN ASIA/PACIFIC FROM 2017–2020 AS PART OF THE ATLAS GLOBAL SURVEILLANCE PROGRAm
28. Competition of bacteriophage polypeptides with native replicase proteins for binding to the DNA sliding clamp reveals a novel mechanism for DNA replication arrest in Staphylococcus aureus
29. Sequencing of porA from clinical isolates of Neisseria meningitidis defines a subtyping scheme and its genetic regulation
30. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene
31. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus
32. Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis
33. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005–2008
34. Triaminotriazine DNA helicase inhibitors with antibacterial activity
35. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)
36. Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci
37. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus
38. Bisphosphonated Benzoxazinorifamycin Prodrugs for the Prevention and Treatment of Osteomyelitis.
39. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters
40. Antimicrobial drug discovery through bacteriophage genomics.
41. Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates
42. Effects of disruption of xylanase-encoding genes on the xylanotic system of Streptomyces lividans.
43. Supplier sustainability performance evaluation and selection: A framework and methodology.
44. Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
45. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
46. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.
47. Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections.
48. Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci.
49. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
50. Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.